# A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

> **NCT06741644** · PHASE1,PHASE2 · RECRUITING · sponsor: **CStone Pharmaceuticals** · enrollment: 660 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** CS2009
- **DRUG:** CS2009
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Etoposide
- **DRUG:** Nab-paclitaxel
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Docetaxel
- **DRUG:** Leucovorin
- **DRUG:** 5-FU
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06741644
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-24
- **Primary completion:** 2027-01
- **Final completion:** 2028-01
- **Target enrollment:** 660 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06741644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06741644, "A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06741644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*